A simplified bi-monthly regimen with leucovorin (LV) and 5-Fluorouracil (5FU) for metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Tournigand, C
de Gramont, A
Louvet, C
Andre, T
Carola, E
Gilles-Amar, V
Maindrault-Goebel, F
Lotz, JP
Molitor, JL
机构：
[1] Hop St Antoine, GERCOR, F-75571 Paris, France
[2] Hop Tenon, F-75970 Paris, France
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
189
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [1] Does the dose of leucovorin (LV) matter with 5-fluorouracil (5FU) in colorectal cancer (CRC)?
    Biagi, James Joseph
    Coakley, Nadia
    Earle, Craig
    Erlichman, Charles
    Fields, Anthony L. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer.
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fernández, R
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 49
  • [4] AN INTERMITTENT LEUCOVORIN CALCIUM (LV) 5-FLUOROURACIL (5FU) REGIMEN FOR ADVANCED ADENOCARCINOMA OF THE COLON
    BRUCKNER, HW
    HART, R
    SPIGELMAN, M
    FEUER, R
    HOLLAND, JF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 202 - 202
  • [5] Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
    Smid, Kees
    Meijer, Erik
    Pham, Thang V.
    de Reus, Inge
    Piersma, Sander R.
    Peters, Godefridus J.
    Jimenez, Connie R.
    CANCER RESEARCH, 2015, 75
  • [6] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [7] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [8] Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy
    Falcone, A
    Pfanner, E
    Brunetti, I
    Allegrini, G
    Lencioni, M
    Galli, C
    Masi, G
    Danesi, D
    Antonuzzo, A
    Del Tacca, M
    Conte, PF
    TUMORI, 1998, 84 (06) : 666 - 668
  • [9] A multicenter phase II trial of bi-weekly irinotecan (CPT11), infusional 5-fluorouracil (5FU) and leucovorin (LV) with oral tegafur/uracil (UFT) for metastatic colorectal cancer (MCRC).
    Kono, T
    Tomita, I
    Kasai, S
    Chisato, N
    Asama, T
    Kamiya, K
    Yamamoto, Y
    Kawabata, N
    Lhara, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 285S - 285S
  • [10] A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma
    Gennatas, C.
    Papaxoinis, G.
    Michalaki, V.
    Mouratidou, D.
    Andreadis, Ch.
    Tsavaris, N.
    Pafiti, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 538 - 544
12345